Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study

Stefania Chiappini,Clara Cavallotto,Alessio Mosca,Francesco Di Carlo,Tommaso Piro,Giulia Giovannetti,Arianna Pasino,Mariachiara Vicinelli,Chiara Lorenzini,Mariapia Di Di Paolo,Maria Pepe,Marco Di Nicola,Valerio Ricci,Mauro Pettorruso,Giovanni Martinotti

DOI: https://doi.org/10.3390/ph17040535

IF: 4.6

2024-04-22

Pharmaceuticals

Abstract:Background: Dual disorders (DDs) involve the coexistence of a substance use disorder (SUD) with another mental illness, often from the psychotic and affective categories. They are quite common in clinical practice and present significant challenges for both diagnosis and treatment. This study explores the effectiveness of brexpiprazole, a third-generation antipsychotic, in an Italian sample of individuals diagnosed with schizophrenia spectrum disorder and a comorbid SUD. Methods: Twenty-four patients, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and enrolled in several Italian hospitals, underwent a psychometric assessment at baseline (T0) and one month (T1) after starting brexpiprazole treatment administered at a mean dosage of 2 mg/day. Results: Brexpiprazole demonstrated significant reductions in psychopathological burden (Positive and Negative Syndrome Scale/PANSS total score: p < 0.001). Positive (p = 0.003) and negative (p = 0.028) symptoms, substance cravings (VAS craving: p = 0.039), and aggression (MOAS scale: p = 0.003) were notably reduced. Quality of life improved according to the 36-item Short Form Health Survey (SF-36) subscales (p < 0.005). Conclusions: This study provides initial evidence supporting brexpiprazole's efficacy and safety in this complex patient population, with positive effects not only on psychopathology and quality of life, but also on cravings. Further studies involving larger cohorts of subjects and extended follow-up periods are needed.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

This paper aims to explore the efficacy and safety of brexpiprazole in patients with schizophrenia spectrum disorders and comorbid substance use disorder (SUD). The study evaluates the effects of this novel third-generation antipsychotic through a prospective, multicenter real-world research approach. ### Research Background and Objectives - **Research Background**: Dual Disorders (DDs), the co-occurrence of mental illness and substance use disorder, are very common in clinical practice and pose significant challenges for diagnosis and treatment. These patients often suffer from schizophrenia or affective disorders along with some form of substance abuse problem. - **Research Objectives**: To evaluate the efficacy and safety of brexpiprazole in patients with schizophrenia spectrum disorders and comorbid SUD. ### Main Findings - **Study Design**: Included 24 patients with schizophrenia spectrum disorders who met the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and had comorbid SUD. All patients received an average dose of 2 mg/day of brexpiprazole. - **Main Results**: - After 1 month of treatment, the total burden of psychiatric symptoms (Positive and Negative Syndrome Scale, PANSS total score) significantly decreased (p < 0.001). - Positive symptoms (p = 0.003), negative symptoms (p = 0.028), substance craving (VAS craving: p = 0.039), and aggressive behavior (Modified Overt Aggression Scale, MOAS: p = 0.003) all significantly reduced. - Quality of life improved in multiple dimensions according to the 36-item Short Form Health Survey (SF-36) (p < 0.005). - **Conclusion**: Preliminary evidence suggests that brexpiprazole has good efficacy and safety in this complex patient population, improving psychiatric symptoms and quality of life while reducing substance craving. Further research is needed to validate these findings, including larger sample sizes and longer follow-up periods. ### Significance This study provides valuable information for understanding the application of brexpiprazole in patients with schizophrenia and comorbid substance use disorder. It demonstrates the potential of this medication to address both psychiatric symptoms and substance abuse issues, thereby improving the overall quality of life for patients. However, the study also emphasizes the need for more evidence to support its long-term effects and broader application.

Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

A Prospective, Multicentric, Real-World Investigation

Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

Brexpiprazole Augmentation in Treatment Resistant OCD: Safety and Efficacy in an Italian Sample

Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists

The Role of Partial Agonists and Specifically Cariprazine in Dual Disorders

Cariprazine in Bipolar Disorder and Substance Use: A Dual Approach to Treatment?

[Brexpiprazole for treatment of schizophrenia: a critical literature study]

A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder

Dopamine D2 receptor partial agonists in the treatment of schizophrenia -example of brexpiprazole

Double-blind,double-dummy and randomized controlled study of aripiprazole in the treatment of acute schizophrenia

Psychosocial Interventions for Individuals With Comorbid Psychosis and Substance Use Disorders: Systematic Review and Meta-analysis of Randomized Studies

Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study

New drugs in the treatment of dual psychosis: use of cariprazine in schizophrenia, other psychotic disorders and use of cocaine. A case series in a specific outpatient psychiatric clinic for substance use disorders.

A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia

Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder

Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response

Comparative Short- and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment-Resistant Unipolar Depression: An Observational Study

Treatment satisfaction and effectiveness of Lurasidone on quality of life and functioning in adult patients with schizophrenia in the real-world Italian clinical practice: a prospective 3-month observational study